Stock Analysis
Ryvu Therapeutics (WSE:RVU) Full Year 2023 Results
Key Financial Results
- Revenue: zł67.3m (down 1.7% from FY 2022).
- Net loss: zł92.1m (loss widened by 9.9% from FY 2022).
- zł3.98 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Ryvu Therapeutics Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 2.0%.
Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Performance of the market in Poland.
The company's shares are down 2.4% from a week ago.
Risk Analysis
We should say that we've discovered 2 warning signs for Ryvu Therapeutics (1 makes us a bit uncomfortable!) that you should be aware of before investing here.
Valuation is complex, but we're helping make it simple.
Find out whether Ryvu Therapeutics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:RVU
Ryvu Therapeutics
A clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology.